Back to search
FDAFDA · Food and drugs·Recall number D-0216-2018

Shiseido Future Solution LX Discovery Set contains SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc oxide 15.4%), packaged in 15 mL tubes, Shiseido Americas Corporation Dist. New York, NY 10022,

Published January 24, 2018 · Recall initiated: December 14, 2017

Summary

FDA records drug Class II recall D-0216-2018, published January 24, 2018 and initiated December 14, 2017. Recalling firm: SHISEIDO AMERICA INC.; Status: Terminated; Reported quantity: N/A; Lot: SKU#: 95167. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

GMP Deviations: manufacturing of API material did not meet GMP and quality requirements.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SHISEIDO AMERICA INC.
Distributor
Product was distributed nationwide.
Lot
SKU#: 95167
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Shiseido Future Solution LX Discovery Set contains SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc oxide 15.4%), packaged in 15 mL tubes, Shiseido Americas Corporation Dist. New York, NY 10022, recalled?

Yes. FDA published recall D-0216-2018 on January 24, 2018. Reported hazard: GMP Deviations: manufacturing of API material did not meet GMP and quality requirements.

What should I do if I have this product?

Voluntary: Firm initiated · Letter